Babies born to mothers with HNF1A-MODY, a rare genetic form of diabetes, are significantly larger than average in about 40% of pregnancies, according to a Gram Research analysis of 183 cases. Using insulin during pregnancy reduced this risk to 35%, compared to 64% with diet-only management. Standard diabetes care works for most women with this condition, but tight blood sugar control and careful newborn monitoring are essential, especially when the mother carries the gene mutation.

A Gram Research analysis of 183 pregnancies involving parents with HNF1A-MODY, a rare genetic form of diabetes, found that babies born to affected mothers were significantly larger than average in about 40% of cases. Interestingly, using insulin during pregnancy reduced this risk compared to diet-only management. The study shows that standard diabetes care during pregnancy works for most women with this genetic condition, but doctors should pay special attention to blood sugar control and watch newborns carefully for low blood sugar, especially when the mother carries the gene mutation.

Key Statistics

A 2026 cohort study of 183 pregnancies involving parents with HNF1A-MODY found that 39.4% of babies born to affected mothers were large for gestational age, compared to 15% in the general population.

Among mothers with HNF1A-MODY treated with insulin, 35.1% had large babies, compared to 64.3% of mothers managed with diet alone, according to the 2026 study of 183 pregnancies.

In the 2026 analysis of HNF1A-MODY pregnancies, persistent low blood sugar in newborns occurred in 8 cases born to mothers with poor blood sugar control, compared to zero cases in the paternal inheritance group.

Mothers with HNF1A-MODY in their third trimester required an average insulin dose of 0.61 units per kilogram of body weight per day, based on 26 pregnancies reviewed in the 2026 study.

The Quick Take

  • What they studied: How well standard diabetes treatment works during pregnancy for women with HNF1A-MODY, a rare genetic form of diabetes, and what happens to their babies
  • Who participated: 183 babies born to 73 parents with confirmed HNF1A-MODY (142 babies from affected mothers, 41 from affected fathers). Researchers looked back at medical records and pregnancy information from these families
  • Key finding: Babies born to mothers with HNF1A-MODY were significantly larger than normal in 39.4% of cases, compared to just 15% in the general population. Using insulin reduced this risk to 35.1%, while diet-only management had a 64.3% rate of large babies
  • What it means for you: If you have HNF1A-MODY and are planning pregnancy, insulin treatment appears safer than diet alone for preventing oversized babies. However, this is a rare condition, so talk with your diabetes and pregnancy doctors about your specific situation

The Research Details

Researchers reviewed medical records and pregnancy information from 73 families where at least one parent had HNF1A-MODY, a rare genetic form of diabetes. They collected information about 183 babies born to these parents, looking at how mothers managed their blood sugar during pregnancy, their blood sugar test results, how much weight they gained, and what happened to the babies at birth.

The study compared outcomes between babies born to mothers with the mutation versus fathers with the mutation. They also looked at whether using insulin versus diet-only management made a difference in pregnancy outcomes. The researchers measured several things: blood sugar control (using HbA1c and glucose readings), baby birthweight, whether babies were born early or late, and whether newborns developed low blood sugar after birth.

This type of study, called a retrospective cohort study, looks backward at what already happened rather than following people forward in time. This approach is useful for rare conditions like HNF1A-MODY where finding enough patients to study is challenging.

HNF1A-MODY is extremely rare, so doctors don’t have much information about the best way to manage pregnancy in these women. This study provides real-world evidence about what actually happens when women with this genetic diabetes get pregnant and how different treatment approaches affect their babies. Understanding these outcomes helps doctors counsel women with this condition about what to expect and how to reduce risks

This study looked back at existing medical records rather than following patients forward, which means some information may be incomplete or rely on memory. The sample size is relatively small for statistical analysis, particularly when looking at subgroups. However, because HNF1A-MODY is so rare, this represents a meaningful collection of cases. The researchers had access to actual medical records for most participants, which increases reliability. The findings about insulin being better than diet are based on smaller numbers (34 insulin-treated pregnancies), so these results need confirmation in future studies

What the Results Show

The most striking finding was that babies born to mothers with HNF1A-MODY were much larger than expected. About 39.4% of babies born to affected mothers were large for gestational age (meaning bigger than normal for how far along the pregnancy was), compared to only 15% in the general population. This difference was statistically significant, meaning it’s unlikely to be due to chance.

Treatment approach made a real difference. Among mothers treated with insulin, 35.1% had large babies, while mothers managed with diet alone had large babies in 64.3% of cases. This suggests insulin treatment provides better protection against oversized babies. In the smaller group of insulin-treated pregnancies that researchers could analyze in detail, several factors predicted which babies would be larger: higher average blood sugar readings, higher insulin doses needed in the third trimester, higher HbA1c levels (a measure of long-term blood sugar control), and greater maternal weight gain during pregnancy.

Newborns occasionally experienced low blood sugar after birth, which occurred more often when the mother carried the mutation herself. Eight babies born to mothers with dysglycaemia (poor blood sugar control) developed persistent low blood sugar, compared to none in the paternal inheritance group. This difference approached statistical significance and suggests maternal blood sugar control during pregnancy affects newborn metabolism.

The study found that insulin doses in the third trimester averaged 0.61 units per kilogram of body weight per day, which is helpful information for doctors managing these pregnancies. The fact that birthweight was largely similar to the general population in many cases suggests that HNF1A-MODY doesn’t automatically cause large babies, but rather poor blood sugar control during pregnancy does. This is an important distinction because it means the outcome is modifiable through better glucose management

Previous medical literature suggested that HNF1A-MODY rarely causes large babies or newborn low blood sugar, and that standard diabetes management should work fine. This study confirms that standard care is generally sufficient, but reveals that the risk of large babies is actually higher than previously thought, especially in mothers with poor blood sugar control. The finding that insulin is more effective than diet alone aligns with general diabetes in pregnancy research, but this is the first detailed look at this specific genetic form of diabetes

This study looked backward at medical records rather than following women forward, which means some information may be missing or inaccurate. The sample size is small, especially when breaking down results by treatment type or other factors. Some analyses included only 26 to 34 pregnancies, making it harder to draw firm conclusions. The study relied partly on parents remembering details about their pregnancies, which can be unreliable. Because this is a rare condition, results may not apply to all people with HNF1A-MODY, and findings need confirmation in larger studies before changing clinical practice

The Bottom Line

Women with HNF1A-MODY who are pregnant or planning pregnancy should work closely with both their diabetes doctor and obstetrician to achieve tight blood sugar control. Insulin treatment appears more effective than diet alone for preventing large babies. Newborns should be monitored carefully for low blood sugar, especially if the mother carries the mutation. These recommendations are based on a small study of a rare condition, so individual counseling with your medical team is essential (moderate confidence level)

This research is most relevant to women with HNF1A-MODY who are pregnant or planning pregnancy, their partners, and their healthcare providers. Because HNF1A-MODY is rare, most people won’t be directly affected. However, the findings may also interest doctors who care for women with other genetic forms of diabetes during pregnancy. Family members of people with HNF1A-MODY should know that genetic counseling is important if they’re considering pregnancy

Blood sugar control improvements can affect fetal growth throughout pregnancy, but the third trimester is particularly important. Doctors typically see changes in insulin requirements within weeks of starting treatment. Newborn low blood sugar typically appears within the first few hours after birth, so careful monitoring in the delivery room and nursery is critical

Frequently Asked Questions

What is HNF1A-MODY and how does it affect pregnancy?

HNF1A-MODY is a rare genetic form of diabetes caused by a mutation in the HNF1A gene. During pregnancy, women with this condition have higher rates of large babies (39.4% versus 15% normally) and newborns may develop low blood sugar. Standard diabetes management usually works, but tight blood sugar control is important

Is insulin or diet better for managing HNF1A-MODY during pregnancy?

Insulin treatment appears significantly more effective than diet alone. A 2026 study found that insulin reduced large baby risk to 35.1%, compared to 64.3% with diet-only management. Talk with your diabetes and pregnancy doctors about which approach is best for you

What should I expect if I have HNF1A-MODY and get pregnant?

You’ll need close monitoring of blood sugar throughout pregnancy, with insulin likely recommended. Your baby will be monitored carefully at birth for low blood sugar, especially if you carry the mutation. Most pregnancies proceed normally with proper management, but your healthcare team should counsel you on specific risks

Can my baby inherit HNF1A-MODY from me?

Yes, there’s a 50% chance your baby will inherit the HNF1A mutation if you carry it. Babies who inherit the mutation may develop diabetes later in life, but this doesn’t affect pregnancy management. Genetic counseling can help you understand inheritance patterns and plan for your child’s future health

Why do babies born to mothers with HNF1A-MODY become large?

Large babies result from poor blood sugar control during pregnancy, not from the genetic mutation itself. High maternal blood sugar causes the baby’s pancreas to produce extra insulin, which promotes growth. Better blood sugar control with insulin treatment significantly reduces this risk

Want to Apply This Research?

  • If you have HNF1A-MODY and are pregnant, track daily blood sugar readings before and after meals, along with insulin doses used. Record these in your app with timestamps to identify patterns and share with your healthcare team
  • Set reminders to check blood sugar at consistent times each day (fasting, before meals, and 2 hours after meals). Log results immediately in the app rather than relying on memory. Share weekly summaries with your diabetes care team to adjust treatment as needed
  • Use the app to track HbA1c results every 4 to 6 weeks during pregnancy, weight gain patterns, and any symptoms of high or low blood sugar. Create alerts for out-of-range readings and schedule regular check-ins with your healthcare provider to review trends

This article summarizes research about HNF1A-MODY and pregnancy outcomes. It is not medical advice. HNF1A-MODY is a rare genetic condition requiring specialized care. If you have HNF1A-MODY or suspect you might, consult with an endocrinologist and maternal-fetal medicine specialist before, during, and after pregnancy. Pregnancy management should be individualized based on your specific medical history, blood sugar patterns, and other health factors. All treatment decisions should be made in consultation with your healthcare team.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Glycaemic Management and Pregnancy Outcomes in HNF1A-MODY. , Diabetes, obesity & metabolism (2026). PubMed 42864258 | DOI
Topics
HNF1A-MODY genetic diabetes pregnancy large for gestational age neonatal hypoglycemia insulin treatment pregnancy diabetes management pregnancy rare genetic diabetes gestational diabetes alternatives